Omega is a private investment vehicle focusing on innovation across sectors including healthtech, fintech, and real estate development.
Portfolio
3
companies
EyeBio
EyeBio develops a pipeline of novel therapies for retinal and eye diseases.
Meniga
Meniga provides digital banking and personal finance management solutions for major financial institutions.
NRG Therapeutics
NRG Therapeutics develops mitochondrial-targeted treatments for neurodegenerative conditions.
Bernard Davitian
Partner
The financing round was led by SV Health Investors and will fund initial human trials for the company lead candidate in ALS and Parkinson's.
"Developing new drugs to treat neurological diseases is very challenging, but is receiving increased interest given the high unmet medical need and growing prevalence in ageing populations."
The Series D round was backed by European banks and investors including Groupe BPCE and Crédito Agrícola.
"We are excited to continue our partnership with Meniga, which currently empowers the digital banking experience for our over 10 million users, and provides more than 100 million insights for our users every year. We are looking forward to seeing the firm’s continued focus on enrichment as well as personalised insights. These capabilities are critical for all BPCE banks to effectively engage with their end users and we have seen firsthand how Meniga’s solution is a key component for banks to succeed."
Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC joined the financing round to support accelerated development of the company pipeline.
"We look forward to partnering with David Guyer and the world-class team at EyeBio to contribute to building a great company together"
